Glioblastoma multiforme (GBM) is a devastating brain cancer with a mean survival of only 14.6 months. Current standard-of-care therapies provide only palliation, indicating an urgent need to develop more effective therapeutic options. GBMs display a hierarchy of differentiation states within the tumor, similar to normal brain development processes. Molecular signals that initiate and maintain gliomas commonly overlap with those involved in stem cell development, and indeed accumulating evidence suggests that GBM stem-like cells (GSCs) contribute to tumor propagation, recurrence and the eventual loss of life associated with these lesions. However, molecular mechanisms that regulate GSC survival and therapy resistance remain poorly understood, and this has hampered efforts to develop effective therapies that prevent GBM growth and recurrence. Our recent studies and preliminary data have discovered a novel molecular signaling cascade that may control the survival, proliferation, and therapy resistance of GSCs. This pathway involves the mitotic kinase MELK, methyl transferase EZH2, and oncogenic transcription factor STAT3. Importantly, dysregulation of this pathway accelerates GSC growth and promotes GBM malignancy, and are tightly associated with poor patient outcome. This project will interrogate the role of this MELK-EZH2-STAT3 pathway in GSC self-renewal, survival, GBM progression, and radiation resistance. Our data strongly indicate that inhibition of the MELK-EZH2-STAT3 signaling axis by targeting the upstream effector MELK may have profound clinical implications since it can simultaneously block multiple oncogenic signaling pathways all of which are the well-known therapeutic targets. Toward this goal, we have developed a small-molecule MELK inhibitor that could decrease GSC survival and tumor growth in vivo. We anticipate that this study will yield a new paradigm for GSC biology and a novel therapeutic approach to target key regulators of GSC, which may lead to the translation into improved therapies.

Public Health Relevance

Glioblastoma multiforme (GBM) is a devastating cancer with a mean survival of only 14.6 months and few therapeutic options. Standard treatment regimen for GBM is maximal surgical resection followed by radiotherapy and chemotherapy, which has only a palliative effect on patient's survival. Thus, more effective treatment is urgently needed. This proposal will determine the molecular mechanisms of the newly identified MELK/EZH2/STAT3 pathway in GBM cells and examine whether targeting this pathway would be a safe and efficient therapeutic strategy for GBM.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS083767-02
Application #
8686100
Study Section
Special Emphasis Panel (ZRG1-BMCT-C (01))
Program Officer
Fountain, Jane W
Project Start
2013-07-01
Project End
2018-06-30
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
2
Fiscal Year
2014
Total Cost
$252,565
Indirect Cost
$43,854
Name
Ohio State University
Department
Neurosurgery
Type
Schools of Medicine
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Huang, Tianzhi; Alvarez, Angel A; Pangeni, Rajendra P et al. (2016) A regulatory circuit of miR-125b/miR-20b and Wnt signalling controls glioblastoma phenotypes through FZD6-modulated pathways. Nat Commun 7:12885
Cheng, Peng; Wang, Jia; Waghmare, Indrayani et al. (2016) FOXD1-ALDH1A3 Signaling Is a Determinant for the Self-Renewal and Tumorigenicity of Mesenchymal Glioma Stem Cells. Cancer Res 76:7219-7230
Kim, Sung-Hak; Ezhilarasan, Ravesanker; Phillips, Emma et al. (2016) Serine/Threonine Kinase MLK4 Determines Mesenchymal Identity in Glioma Stem Cells in an NF-κB-dependent Manner. Cancer Cell 29:201-13
Gallego-Perez, Daniel; Chang, Lingqian; Shi, Junfeng et al. (2016) On-Chip Clonal Analysis of Glioma-Stem-Cell Motility and Therapy Resistance. Nano Lett 16:5326-32
Lee, Jin-Ku; Chang, Nakho; Yoon, Yeup et al. (2016) USP1 targeting impedes GBM growth by inhibiting stem cell maintenance and radioresistance. Neuro Oncol 18:37-47
Ouchi, Rie; Okabe, Sachiko; Migita, Toshiro et al. (2016) Senescence from glioma stem cell differentiation promotes tumor growth. Biochem Biophys Res Commun 470:275-81
Lee, Jin-Ku; Nam, DO-Hyun; Lee, Jeongwu (2016) Repurposing antipsychotics as glioblastoma therapeutics: Potentials and challenges. Oncol Lett 11:1281-1286
Sa, Jason K; Yoon, Yeup; Kim, Misuk et al. (2015) In vivo RNAi screen identifies NLK as a negative regulator of mesenchymal activity in glioblastoma. Oncotarget 6:20145-59
Cheng, Peng; Phillips, Emma; Kim, Sung-Hak et al. (2015) Kinome-wide shRNA screen identifies the receptor tyrosine kinase AXL as a key regulator for mesenchymal glioblastoma stem-like cells. Stem Cell Reports 4:899-913
Ganguly, Ranjit; Mohyeldin, Ahmed; Thiel, Jordyn et al. (2015) MELK-a conserved kinase: functions, signaling, cancer, and controversy. Clin Transl Med 4:11

Showing the most recent 10 out of 25 publications